Related Experiment Video
Updated: Jul 7, 2026

Modulating Cognition Using Transcranial Direct Current Stimulation of the Cerebellum
Published on: February 15, 2015
Cerebellar cognitive affective syndrome associated with topiramate
Hanne Baillieux1, Werner Verslegers, Philippe Paquier
1Department of Linguistics, Vrije Universiteit Brussel, Brussels, Belgium.
Abstract:
The cerebellar cognitive affective syndrome (CCAS) represents a spectrum of cerebellar-induced neurocognitive and affective disturbances. In this report a patient is described who developed CCAS under a treatment with standard daily dose of the anti-epileptic drug topiramate (TPM). Cognitive disturbances consisted of impaired visuo-spatial memory, concentration deficits and executive dysfunctions. Behavior and affect were characterized by marked mood-swings and several disinhibited symptoms. After a gradual discontinuation of treatment with topiramate, a complete remission of the cognitive and affective symptoms was observed within 6 weeks. Functional neuroimaging studies by means of SPECT were conducted 2 weeks and 8 months following TPM discontinuation. This case report seems to suggest that functional disruption of the cerebello-cerebral circuitry, leading to CCAS, can follow treatment with topiramate.
Related Concept Videos
Seizures ll: Types
Hepatic Encephalopathy
Cognitive Therapy
Seizures l: Introduction
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Cognitive Enhancers: Cholinesterase Inhibitors and NMDA Receptor Antagonists